Choroidal ischemia as one cardinal sign in giant cell arteritis

Antonio M. B. Casella1*, Ahmad M. Mansour2, Souza EC3, Rodrigo B. do Prado1, Rodrigo Meirelles4, Keye Wong5, Salma Yassine6 and Mário Luiz R. Monteiro3

Abstract

Purpose: To describe chorioretinal signs in a case series of Giant Cell Arteritis (GCA).

Methods: This is a multicenter retrospective observational case series with GCA that presented with a headache and an abrupt, unilateral loss in vision. Workup included temporal artery biopsies, intravenous fluorescein angiography, optical coherence tomography (OCT), optical coherence tomography angiography (OCTA), blood levels of erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).

Results: There are a total of 8 GCA instances presented. Average age was 74.5. (Range 68–83 years). The patients reported that one eye’s visual loss had suddenly started, along with a fresh headache and other systemic symptoms. Eight patients exhibited choroidal ischemia, five paracentral acute middle maculopathy (PAMM) lesions, five cotton wool spots, four anterior ischemic optic neuropathy, and one central retinal arterial occlusion at the time of presentation. The average ESR at presentation was 68 mm/hr (range 4–110), and 4/6 individuals had a significant increase. The mean CRP level was 6.2 mg/dL (range 2.0–15.4), and the level was always over the normal range. All patients’ temporal artery biopsies were positive.

Conclusion: Alongside PAMM lesions, cotton wool spots, anterior ischemic optic neuropathy, and central retinal artery occlusion, choroidal ischemia is a key angiographic indicator in the diagnosis of GCA. It may be crucial to recognize these typical ischemic chorioretinal signs while diagnosing GCA.

Keywords: Giant cell arteritis, Choroidal hypoperfusion, Paracentral acute middle maculopathy, Fluorescein angiography, OCTA, Arteritic anterior ischemic optic neuropathy, Cotton-wool spots

Introduction

Giant cell arteritis (GCA) is a medium to large vessel granulomatous vasculitis of autoimmune etiology with predilection to the cranial branches of the aortic artery [1–32]. GCA has multisystem manifestations (new onset temporal headache, jaw claudication, low grade fever), propensity to the elderly population with an average age of onset of 75 years, and a strong female predominance [1, 2]. Since the involvement of the contralateral eye can increase to 60% when left untreated [8], visual loss is the most feared and irreversible complication of GCA, and therapy with a high-dose corticosteroid (and most recently tocilizumab) lowers the incidence of blindness. Vision loss results from either central retinal artery occlusion (CRAO) or posterior ciliary artery (PCA) occlusion manifesting as arteritic anterior ischemic optic neuropathy (A-AION) [10, 12]. The only way to diagnose many ischemic events occurring outside of the papillo-macular area is with intravenous fluorescein angiography, indocyanine angiography or optical coherence tomography angiography (OCTA). These events can involve the choroid (choroidal ischemia) [11, 12] or the retina.

*Correspondence: mbcasella@gmail.com

1 Department of Surgery, Health Sciences Center, Londrina State University, 60 Robert Koch Av 86038, Londrina, Paraná, Brazil
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
| Case | Sex | Age | Visual Complaint | Systemic Signs | Initial VA OD | Initial VA OS | Final VA OD | Final VA OS | FU   | ESR/CRP | Choroidal Ischemia | CRAO | PAMM | CWS | A-AION |
|------|-----|-----|-----------------|----------------|---------------|---------------|-------------|-------------|------|---------|-------------------|------|-------|------|---------|
| 1    | F   | 70  | Visual loss OS  | Yes            | 20/20         | CF            | 20/20       | 20/200      | 48   | 99/6.3  | OU                | OD   | OD    | OU   | OD      |
| 2    | F   | 78  | Visual loss OS  | Yes            | CF            | 20/80         | 20/60       | 20/25       | 60   | 74/2.5  | OU                | No   | OU    | OU   | OU      |
| 3    | F   | 75  | Visual loss OS  | Yes            | 20/50         | 20/30         | 20/25       | 20/20       | 12   | 60/10.4 | OU                | No   | OU    | OS   | OD      |
| 4    | F   | 68  | Visual loss OS  | Yes            | 20/70         | 20/20         | 20/25       | 20/20       | 36   | 110/7.5 | OD                | No   | OU    | No   | OD      |
| 5    | F   | 72  | Visual loss OS  | Yes            | 20/20         | 20/800        | 20/20       | 20/200      | 36   | 4/2.0   | OU                | No   | No    | OU   | No      |
| 6    | F   | 79  | Visual loss OS  | Yes            | 20/30         | CF            | 20/30       | 20/500      | 3    | 92/15.4 | OS                | No   | OS    | OS   | OS      |
| 7    | M   | 71  | Visual loss OS  | Yes            | 20/20         | 20/20         | 20/20       | 20/800      | 3    | 59/2.9  | OS                | No   | No    | No   | OS      |
| 8    | M   | 83  | Visual loss OS  | Yes            | 20/25         | 20/40         | 20/25       | 20/40       | 6    | 48/2.8  | OS                | No   | No    | No   | OS      |

F female, M male, OD oculus dexter, OS oculus sinister, OU oculus uterque, VA best spectacle corrected visual acuity, CF counter fingers, ESR erythrocyte sedimentation rate (mm/hr), CRP C-reactive protein (mg/dL), PAMM paracentral acute middle maculopathy, CWS cotton-wool spots, A-AION arteritic anterior ischemic optic neuropathy, CRAO central retinal artery occlusion, FU follow up (months)
(cotton-wool spots (CWS) and paracentral acute middle maculopathy (PAMM) [13–16]. The purpose of this study is to describe such circulatory ischemic events in a case series of GCA using multimodal imaging of the choroidal and retinal circulation.

Methods
This multicenter, retrospective, observational case study examined the multimodal imaging results for 16 eyes of 8 patients treated for GCA at 6 ophthalmology clinics between January 2013 and December 2020. The descriptive study received ethical committee approval, the researchers agreed to a confidentiality agreement, and informed consent was not required. Data were collected from comorbidities, constitutional symptoms, acute phase reactant tests (erythrocyte sedimentation rate (Westergren) (ESR) and C-reactive protein (CRP), initial and final best corrected visual acuity.

The American College of Rheumatology categorization criteria, which call for three or more of the following signs or symptoms, were used to diagnose GCA: (1) age ≥ 50 years; (2) headache of new onset; (3) temporal artery tenderness to palpation and decreased pulsation; (4) ESR ≥ 50 mm/hr; and (5) temporal artery biopsy showing a predominance of mononuclear cell infiltration or granulomatous inflammation of the vessel wall, usually but not necessarily accompanied by multinucleated giant cells. An elevated level for CRP is set as a value above 1.0 mg/dL.

At presentation, patients underwent fundus photography, near-infrared reflectance (Spectralis, Heidelberg Engineering, Heidelberg, Germany), fluorescein angiography (Carl Zeiss Meditec or Topcon Medical Systems), spectral domain (SD) OCT (Spectralis, Heidelberg Engineering), or swept-source OCT and OCT angiography (OCT-A) (Topcon Medical Systems, Oakland, New Jersey, USA). The digital images of each patient were grouped for a multimodal study.

Results
Eight patients (16 eyes) were identified and collected for the study, 6 were women (75%) and the age ranged from 68 to 83 years (mean 74.5 years). All patients reported constitutional symptoms (headache, scalp tenderness, neck pain, fever, weight loss, malaise, fatigue, jaw claudication) (Table 1). ESR and CPR values showed moderate elevation in most cases. Ocular ischemic damage was noted to be bilateral in 5 patients (62.5%). Choroidal ischemia was documented in 12 eyes (75%), PAMM, CWS and A-AION in 8 eyes each (50%), and CRAO in one eye (6%) (Table 1). Mean initial best spectacle corrected visual acuity (VA), after conversion to Log MAR, was 20/47 OD (oculus dexter) and 20/115 OS (oculus sinister) (range 20/20 to CF both eyes) while mean final visual acuity was 20/27 OD and 20/94 OS (range 20/20 to 20/80 OD; 20/20 to 20/800 OS) with a mean follow-up of 25.5 months (range 3–60).

Case reports
Case 1
A 70 years-old Caucasian woman presented with visual loss in the OS of 5 days duration. She had pain in the left temple, mandible and neck, loss of strength in the left arm, loss of weight and loss of appetite. Visual acuity (VA) was 20/20 OD and 20/1200 OS, with a left afferent pupillary defect. Macular OCT scans allowed visualization of a hyperreflective band at the level of the inner nuclear layer (INL) sparing the outer nuclear layer and characteristic of paracentral acute middle maculopathy (PAMM) lesions (Fig. 1). OCT-A allowed a superior visualization of the ischemia of the deeper capillary plexus (Fig. 1e). Choroidal ischemia was evident angiographically in OU (oculus ulterque). Pain was reduced by corticosteroid pulse treatment, and VA improvement to 20/200 OS.

Case 2
A Caucasian woman in her 78 s presented with a sudden loss of eyesight OU. She had recently had general malaise, severe weight loss, and jaw claudication, with the dentist attributing her jaw pain to a root-canal issue. No prior history of headaches existed. VA was 20/800 OD and 20/80 OS with a left afferent pupillary defect. Funduscopy OD revealed blurry disc margins and cotton-wool spots while OS had a cherry red spot from CRAO (Fig. 1). OCT-A showed total hyperreflective band with marked macular edema. OCT-A allowed a superior visualization of the ischemia of the deeper capillary plexus (Fig. 1e). Choroidal ischemia was evident angiographically in OU (oculus ulterque). Pain was reduced by corticosteroid pulse treatment, and VA improvement to 20/200 OS.

Case 3
A 75 years-old Caucasian man presented with moderate visual loss OD of few days with visual acuity of 20/50 OD and 20/30 OS, accompanied by temporal headache. Multimodal imaging revealed CWS, PAMM lesions (OCT) and choroidal ischemia (FA) OU (Fig. 3). One week after oral prednisone (60 mg), VA improved to 20/25 OD.
Case 4
A 68 years-old female patient presented to the emergency room for increasing frontal headache of 20 days duration and was reassured following a normal brain MRI. She subsequently noted mandibular pain and VA drop to 20/70 in OD and 20/25 in OS. Moderate edema of the optic disc was noted in OD. FA revealed nasal sectorial choroidal ischemia, disc edema and intact macular perfusion (Fig. 4). With cleared disc edema, pulse corticosteroid therapy improved VA to 20/30 OD in 48 h and 20/25 OD in 11 days.

Case 5
A 72 years-old Caucasian woman complained of sudden visual loss of the OS of 3 days duration preceded by headache of 3 months duration. VA was 20/20 in the OD and 20/800 in the OS. Fundus examination showed normal-looking optic discs and CWS in OU, more intense in OS with some whitening of the retina in the posterior pole. PAMM lesions were visible OU on OCT. Choroidal ischemia was noted angiographically OS. ESR was normal (4 mm/hr) but a CRP was elevated (2.0 mg/dL). An increase in the signal intensity around the left temporal artery was noted on brain MRA. Temporal artery biopsy was positive for GCA. Intravenous pulse therapy with 1 g of methylprednisolone for 5 days was followed by oral prednisone and methotrexate and by VA improving to 20/200 OS.

Case 6
A 79 years-old Caucasian woman complained of visual loss in OU. VA was 20/30 OD and counting fingers OS (Fig. 5). After obtaining a temporal artery biopsy (positive for GCA), corticosteroid treatment allowed partial improvement of the VA to 20/500.

(See figure on next page.)
Fig. 3 (Case 3). The right fundus (A) shows areas of severe delay in choroidal perfusion (B—arrows). The fundus of the left eye shows a cotton wool spot (black arrow - C). There is an inferotemporal sector of choroidal hypoperfusion (arrows - D) in the left eye. A cotton wool spot is noted temporal to the disc in the left eye (arrows 3E).
Case 7
A 71 years-old Caucasian man complained of visual loss OS. VA was 20/20 OD and 20/800 OS. The fundus examination revealed optic discs that were normal. FA revealed hyperfluorescent optic disc and choroidal ischemia OS. VA did not improve, presumably as a result of the delayed start of corticosteroid therapy.

Case 8
An 83 years-old Caucasian man with polymyalgia rheumatica complained of visual loss OS to 20/60. He had a left afferent pupillary defect, optic nerve head swelling, hyperfluorescent optic disc, and angiographic choroidal ischemia. VA OS improved to 20/40 after prompt
administration of corticosteroid. The patient had also polymyalgia rheumatica.

**Discussion**

Compared to other ischemic signs such as PAMM, CWS, or A-AION, choroidal ischemia was seen more frequently in the current case series. The impairment of vascular supply was detected even with a preserved VA. All patients (100%) had VA loss in at least one eye; choroidal infarction was present in 12 eyes (75%); PAMM lesions were present in 8 eyes (50%); CWS was present in 8 eyes (50%); A-AION was present in 8 eyes (50%); and CRAO was present in one eye (6.2%). The understanding of the posterior vascular circulation has improved as a result of this multimodal retinal examination.

In vivo FA studies [10] have shown that the posterior ciliary artery (PCA) supply the choroid (Table 2) in a strictly segmental flow, hence the choroidal vascular bed has watershed zones situated between the various PCAs and the short PCAs. The location of multiple water shed zones of the short PCA in the macular choroid makes the macular choroid more vulnerable to ischemic disorders than other parts of the choroid. Ischemic events in the long PCA impact the choriocapillaris circulation in the periphery and may also be asymptomatic. The recognition of such ischemic damage justifies prompt corticosteroid treatment to prevent further visual damage; in this case series, all patients had choroidal ischemia which may represent a cardinal sign of GCA.

Unrecognized by routine funduscopy, asymptomatic microvascular occlusions in the choroid and retina were discovered using multimodal imaging analysis. There may be more instances of choroidal ischemia with no filling in the periphery than previously believed due to the involvement of the long branches of the PCA (Table 2). Nemiroff et al. [24] noted that swept source OCT-A did provide a simple noninvasive tool to evaluate choroidal ischemia in 3 cases with GCA. While choroidal ischemia is often asymptomatic, ensuing visual loss have been reported when involving the macula or the
papillomacular bundle [25–29]. Despite the fact that choro-
idial ischemia is described as being rare in the present
literature [18, 25–29], it is probable that this irregularity
of the choroidal circulation is frequently overlooked. The
current research and other communications [30, 31] con-
firm that choroidal ischemia is frequently seen. (Table 2).

On one side, our report analyzed the choroidal hypoper-
fusion in a qualitative way using FA. On the other side,
Pellegrini et al. [22] measured quantitatively the choroi-
dal vascularity index in eyes with A-AION using OCT-
A. There was a subtle (4–6%) decrease of the choroidal
vascularity index in eyes with A-AION vs. eyes with non-
A-AION or vs. control eyes. The most recently character-
ized instance of vascular involvement is PAMM [33]. This
hyperreflective parafoveal white band is located at the
level of INL, is best seen on OCT-A, and develops into
deeper layer atrophy as a result of selective obstruction of
the deeper retinal vascular plexus [13]. A-AION, CWS,
and CRAO are well recognized ischemic effects of GCA
(Table 2).

In the literature, there is a significant disparity between
the incidence of fundus abnormalities among GCA
patients, which ranges from 12 to 70% [32]. For instance,
it appears that the rate of A-AION is overestimated while
the rate of PAMM is understated for several reasons: (1)
referral bias in studies emanating from tertiary centers vs.
population-based studies; (2) the prevalence of PAMM
lesions is increasing as a result of the development of new
technologies (OCT, OCT-A).

GCA is a systemic disease of variable presentation and
duration. Marked elevation in acute phase reactants is
one hallmark of GCA: 90% have ESR > 50 mm/hr, 10%
have ESR < 50 mm/hr, and only 3.6% have ESR < 30 mm/
hr [17]. Temporal artery biopsy (granulomatous inflam-
mation with giant cells and rupture of the internal elastic
lamina) [3–6] remains the “gold-standard” diagnostic test
with a sensitivity exceeding 90%. Ultrasound of the tem-
poral arteries may substitute for the need of a biopsy in
some cases. Including multimodal imaging can aid in the
rapid identification of GCA even before the biopsy find-
ings are known, facilitating early treatment.

Patients with suspected GCA are advised to undergo
multimodal imaging as it may help in showing asympto-
matic hypoperfusion areas evident findings of A-AION
and CRAO. Multimodal imaging allowed the clinicians
to view topographically the areas of ischemia in GCA.
GCA is a systemic disease of very variable presentation and
high suspicion index is required especially if all labora-
tory and pathology tests are negative or borderline invit-
ing multimodal imaging of the retina and choroid to be
the cardinal index in the diagnosis of GCA.

Conclusions
The discovery of delayed sectorial choroidal filling on
multimodal exams should raise the highest index of
suspicion for GCA. Since it is a medical emergency
and should lead to rapid investigation and aggressive
treatment.

---

### Table 2: Ischemic findings per site and rate in previous literature and updated values

| Ocular ischemia manifestations | TEST | Reported rate % (literature review before 2016/18) | Updated rate% | Author | Publication year | Vascular supply |
|-------------------------------|------|-------------------------------------------------|---------------|--------|-----------------|----------------|
| Optic nerve ischemia          |      |                                                 |               |        |                 |                |
| A-AION                        | Funduscopy; FA | 88–92.3 [18] | 41% (69/170) [31] | Hayreh [31] Glutz von Blotzheim [30] | 2021 | circle of ZinnHaller (short branches PCA) |
| Retinal ischemia              |      |                                                 |               |        |                 |                |
| CRAO                          | Funduscopy; FA | 4–14.1 [18] | 12% (20/170) [31] | Hayreh [31] Glutz von Blotzheim [30] | 2021 | Central retinal artery |
| CWS                           | Funduscopy | up to 33 [18] | 15% (7/47) [30] | Hayreh [31] Glutz von Blotzheim [30] | 1997 | Superficial vascular plexus |
| PAMM                          | OCT; OCT-A | 0 | 17% (16/96) | Mairot [19] | 2021 | Middle capillary plexus |
| Choroidal ischemia            | FA; ICG, SS-OCT | rare | 36% (17/47) | Glutz von Blotzheim [30] | 1997 | long branches PCA |
| Anterior segment ischemia     | Slit lamp exam | very rare | Rare | Tran23 | 2018 | anterior ciliary, arteries, long PCA, anutosmic connections from anterior choroid |

PCA posterior ciliary arteries, A-AION arteritic anterior ischemic optic neuropathy, CRAO central retinal artery occlusion, CWS cotton-wool spot, PAMM paracentral acute middle maculopathy, FA fluorescein angiography, ICG indocyanine green angiography
Choroidal hypoperfusion was present in all current cases of GCA and may represent a cardinal sign. Furthermore, the study reaffirms the importance of detecting PAMM lesions on multimodal retinal imaging, which is an important tool to use to study topographic circulatory disturbances in GCA.

Abbreviations
GCA: Giant cell arteritis; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; A-AION: Arteritic anterior ischemic optic neuropathy; OCT-A: Optical coherence tomography-angiography; FA: Fluorescein angiography; PAMM: Paracentral acute middle maculopathy; OD: Ocus dexter; OS: Ocus sinister; OU: Ocus uterque; INL: Inner nuclear layer; CRAO: Central retinal artery occlusion; CWS: Cotton-wool spots; PCA: Posterior ciliary arteries.

Author contributions
All authors made substantial contributions to the study conception and design. All authors made substantial contributions to acquiring, analyzing, and interpreting the data. AMBC, AMM and MLRM have been involved in drafting the manuscript and all authors have been involved in revising it critically for important intellectual content. All authors read and approved the final manuscript.

Funding
The authors declare no funding was received for this study.

Availability of data and materials
All the data supporting our findings are available through e-mail request from the corresponding author. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Ethical approval for the study was granted by the institutional review board of the Londrina State University under the reference number 4,796,159. The study was performed in accordance with the ethical standards of the Declaration of Helsinki and informed consents were waived by the research ethics committee.

Consent for publication
The research ethics committee waived the consent form for this research. CAAE: 46327621.3.0000.5231 and Seem: 4.796.159, attached to the submission.

Competing interests
Antônio Marcelo Casella is one of the editors-in-chief for International Journal of Retina and Vitreous. The peer-review process for this article was independently handled by another member of the journal editorial board.

Author details
1 Department of Surgery, Health Sciences Center, Londrina State University, 60 Robert Koch Av 86038, Londrina, Paraná, Brazil. 2 Department of Ophthalmology, American University of Beirut, Beirut, Lebanon. 3 Division of Ophthalmology, University of São Paulo, São Paulo, Brazil. 4 Piracicaba Ophthalmological Institute, Piracicaba, São Paulo, Brazil. 5 Retina Associates of Sarasota, Sarasota, FL, USA. 6 Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, USA.

Received: 24 February 2022 Accepted: 12 September 2022

Page 10 of 11

References
1. Waldman CW, Waldman SD, Waldman RA. Giant cell arteritis. Med Clin North Am. 2013;97(2):329–35.
2. Salahari C, Gabriel SE, O’Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995;123:192–4.
3. Aziz S, Al-Ansari A, Bankart J, McFadzean R. Clinical manifestations and laboratory tests in biopsy proven giant cell arteritis in Glasgow. Eur J Intern Med. 2009;20(7):146.
4. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8.
5. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–7.
6. Khalifa M, Karmani M, Jaafoura NG, Kaabia N, Letalief AO, Bahri F. Epidemiological and clinical features of giant cell arteritis in Tunisia. Eur J Intern Med. 2009;20(2):208–12.
7. Almarzouqi SJ, Morgan ML, Lee AG. Treatment of giant cell arteritis. Curr Opin Ophthalmol. 2011;22(6):469–75.
8. Ness T, Bley T, Schmidt W, Lamprecht P. The diagnosis and treatment of giant cell arteritis. Dtsch Arztebl Int. 2013;110:375–85.
9. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003;139(6):505–15.
10. Hayreh SS, Podhaisky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125(4):509–20.
11. Rahman W, Rahman FZ. Giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol. 2005;50(5):415–28.
12. Augsburger J, Heron E, Abanou A, Habas C, Baudoin C, Labbé A. Acute ischemic optic nerve disease: pathophysiology, clinical features and management. J Fr Ophthalmol. 2020;43(2):e41–54. https://doi.org/10.1016/j.jfo.2019.12.002.
13. Chen X, Rahimy E, Sengott RC, Nunes RP, Souza EC, Choudhry N, Cutler NE, Houston SK, Munk MR, Fawzi AA, Mehta S, Hubschman JP, Ho AC, Sarraf D. Spectrum of retinal vascular diseases associated with paracentral acute middle maculopathy. Am J Ophthalmol. 2015;166(1):26–34.
14. Nemiroff J, Phuakkiijwatana N, Sarraf D. Optical coherence tomography angiography of deep capillary ischemia. Dev Ophthalmol. 2016;56:139–45.
15. Rahimy E, Sarraf D. Paracentral acute middle maculopathy spectral-domain optical coherence tomography feature of deep capillary ischemia. Curr Opin Ophthalmol. 2014;25:207–12.
16. Sarraf D, Rahimy E, Fawzi AA, et al. Paracentral acute middle maculopathy: a new variant of acute macular neuroretinopathy associated with retinal capillary ischemia. JAMA Ophthalmol. 2013;131(10):1275–87.
17. Kermani TA, Schmidt J, Crawson CS, Ytterberg SR, Hunder GG, Matteson EL, Warrington KJ. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41(6):866–71.
18. De Smit E, O’Sullivan E, Mackey DA, Hewitt AW. Giant cell arteritis: ophthalmic manifestations of a systemic disease. Graefes Arch Clin Exp Ophthalmol. 2016;254(12):2291–306.
19. Mairat K, Sené T, Lecler A, et al. Paracentral acute middle maculopathy in giant cell arteritis. Retina. 2022;42(3):476–84. https://doi.org/10.1097/IAE.0000000000003339.
20. Yoeruek E, Sazanov P, Tatara O, Weckerle P, Wilhelm H. Anterior ischemic optic neuropathy due to giant cell arteritis with normal inflammatory markers. Graefes Arch Clin Exp Ophthalmol. 2008;246(6):913–5.
21. Martins P, Teixeira V, Teixeira FJ, Canastro M, Palha A, Fonseca JE, Ponte C. Giant cell arteritis with normal inflammatory markers: case report and review of the literature. Clin Rheumatol. 2020;39(10):3115–25.
22. Pellegrini M, Giannaccare G, Bernabei F, Moscardelli F, Schiavi C, Campos EC. Choroidal vascular changes in arteritic and nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 2019;205:43–9.
23. Tran AQ, Yannuzzi NA, Motulsky EH, Zhou XY, Galor A, Dubovy SR, Rosenfeld PI, Lam BL. Swept-source optical coherence tomography angiography of an amalar choroidal infarction in a rare presentation of giant cell arteritis with bilateral corneal edema. Ophthalmic Surg Lasers Imaging Retina. 2018;49(10):157–60.
24. Nemiroff J, Phasukkijwatana N, Vaclavik V, Nagiel A, Holz ER, Sarraf D. The spectrum of Amalric triangular choroidal infarction. Retin Cases Brief Rep. 2017;11:S113-20.
25. Quillen DA, Cantore WA, Schwartz SR, Brod RD, Sassani JW. Choroidal non-perfusion in giant cell arteritis. Am J Ophthalmol. 1993;116(2):171–5.
26. Olal C, Aggarwal S, Ahmed S, Gupta M. Giant cell arteritis presenting as macular choroidal ischaemia. Eye (Lond). 2011;25(1):121–3.
27. Gandhi JS. The island of ischaemia: submacular choroidal nonperfusion in giant cell arteritis. Eye (Lond). 2012;26(3):480–1.
28. Kulkarni P, Shaffu S, Moorthy A, Kapoor B, Kumar P. Giant cell arteritis—a rare ocular presentation. Rheumatol Adv Pract. 2021. https://doi.org/10.1093/rkab/067.030.
29. Cohen S, Gardner F. Bilateral choroidal ischemia in giant cell arteritis. Arch Ophthalmol. 2006;124(6):922.
30. Glutz von Blotzheim S, Borruat FX. Neuro-ophthalmic complications of biopsy-proven giant cell arteritis. Eur J Ophthalmol. 1997;7(4):375–82.
31. Hayreh SS. Giant cell arteritis: its ophthalmic manifestations. Indian J Ophthalmol. 2001;49(4):227–35. https://doi.org/10.4103/ijo.IJO_1681_20.
32. Vodopivec I, Rizzo JJ III. Ophthalmic manifestations of giant cell arteritis. Rheumatology. 2018;57:63–72.
33. Mairot K, Sené T, Lecler A, et al. Paracentral acute middle maculopathy in giant cell arteritis. Retina. 2022;42(3):476–84.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.